



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of : **Confirmation No. 1756**  
Shirou SAWA et al. : Attorney Docket No. 2005\_0232A  
Serial No. 10/525,006 : Group Art Unit 1614  
Filed March 28, 2005 : Examiner Timothy P. Thomas  
AQUEOUS LIQUID PREPARATION :  
CONTAINING 2-AMINO-3-  
(4-BROMOBENZOYL)PHENYLACETIC ACID **Mail Stop: Amendment**

---

**AMENDMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Responsive to the Official Action dated July 18, 2007, the time for responding thereto being extended for three months in accordance with a petition for extension submitted concurrently herewith, please amend the above-identified application as follows:

## Amendments to the Claims

**1-18. (Cancelled)**

**19. (Currently amended)** An aqueous liquid preparation comprising at least the following two components, the first component comprising 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof, and the second component comprising an alkyl aryl polyether alcohol type polymer or a polyethylene glycol fatty acid ester, wherein said liquid preparation is in the form of an eye drop.

**20. (Previously presented)** The aqueous liquid preparation according to claim 19, wherein the alkyl aryl polyether alcohol type polymer is tyloxapol;  
wherein the concentration of the tyloxapol is selected from a range of about 0.01 w/v % to about 0.5 w/v %; and  
wherein the concentration of the 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof is selected from a range of about 0.01 to about 0.5 w/v %.

**21. (Previously presented)** The aqueous liquid preparation according to claim 20, wherein the pharmacologically acceptable salt of 2-amino-3-(4-bromobenzoyl)phenylacetic acid is a sodium salt.

**22. (Previously presented)** The aqueous liquid preparation according to claim 21, wherein the concentration of the 2-amino-3-(4-bromobenzoyl)phenylacetic acid sodium salt is selected from a range of about 0.05 to about 0.2 w/v %.

**23. (Previously presented)** The aqueous liquid preparation according to claim 22, wherein the concentration of the tyloxapol is selected from a range of about 0.01 w/v % to about 0.3 w/v %.

**24. (Previously presented)** The aqueous liquid preparation according to claim 23, wherein the concentration of the 2-amino-3-(4-bromobenzoyl)phenylacetic acid sodium salt is about 0.1 w/v %.

**25. (Previously presented)** The aqueous liquid preparation according to claim 24, wherein the concentration of the tyloxapol is about 0.02 w/v %.

**26. (Previously presented)** The aqueous liquid preparation according to claim 25, wherein the formulation further includes one or more additives selected from the group consisting of a preservative, buffer, thickener, stabilizer, chelating agent, and pH controlling agent.

**27. (Previously presented)** The aqueous liquid preparation according to claim 26, wherein said preservative is benzalkonium chloride; wherein said buffer is boric acid and/or sodium borate; wherein said thickener is polyvinylpyrrolidone; wherein said stabilizer is sodium sulfite; wherein said chelating agent is sodium edetate; and wherein said pH controlling agent is sodium hydroxide.

**28. (Previously presented)** The aqueous liquid preparation according to claim 27, wherein the pH is from about 7 to about 9.

**29. (Previously presented)** The aqueous liquid preparation according to claim 28, wherein the pH is from about 7.5 to about 8.5.

**30. (Cancelled)**

**31. (Previously presented)** The aqueous liquid preparation according to claim 23, wherein the concentration of the 2-amino-3-(4-bromobenzoyl)phenylacetic acid sodium salt is about 0.2 w/v %.

**32. (Previously presented)** The aqueous liquid preparation according to claim 31, wherein the concentration of the tyloxapol is about 0.3 w/v %.

**33. (Previously presented)** The aqueous liquid preparation according to claim 32, wherein the formulation further includes one or more additives selected from the group consisting of a preservative, buffer, thickener, stabilizer, chelating agent, and pH controlling agent.

**34. (Previously presented)** The aqueous liquid preparation according to claim 33, wherein said preservative is benzalkonium chloride; wherein said buffer is boric acid and/or sodium borate; wherein said thickener is polyvinylpyrrolidone; wherein said stabilizer is sodium sulfite; wherein said chelating agent is sodium edetate; and wherein said pH controlling agent is sodium hydroxide.

**35. (Cancelled)**

**36. (Previously presented)** The aqueous liquid preparation according to claim 31, wherein the concentration of the tyloxapol is about 0.02 w/v %.

**37. (Previously presented)** The aqueous liquid preparation according to claim 36, wherein the formulation further includes one or more additives selected from the group

consisting of a preservative, buffer, thickener, stabilizer, chelating agent, and pH controlling agent.

**38. (Previously presented)** The aqueous liquid preparation according to claim 37, wherein said preservative is benzalkonium chloride; wherein said buffer is boric acid and/or sodium borate; wherein said thickener is polyvinylpyrrolidone; wherein said chelating agent is sodium edetate; and wherein said pH controlling agent is sodium hydroxide.

**39. (Withdrawn-currently amended)** A method for stabilizing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof in an aqueous liquid preparation, which comprises incorporating tyloxapol or polyethylene glycol monostearate into an aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof, to obtain an aqueous liquid preparation comprising at least the following two components, the first component comprising 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof, and the second component comprising tyloxapol or polyethylene glycol monostearate, wherein said liquid preparation is in the form of an eye drop.

**40. (Withdrawn-currently amended)** A method for inhibiting decrease in preservative effect of a preservative in an aqueous liquid preparation of 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof, which comprises incorporating tyloxapol or polyethylene glycol monostearate into an aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof and a preservative, to obtain an aqueous liquid preparation comprising at least the following two components, the first component comprising 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof, and the second component comprising tyloxapol or

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.